Insights

Why CTI Biopharma Stock Is Surging Today

What happened
Shares of CTI BioPharma (NASDAQ: CTIC) moved sharply higher after the drugmaker reported first-quarter results Friday morning. Investors were pleased with the initial sales figures for Vonjo, its first approved drug, and pushed the stock price 20.8% higher as of 11:22 a.m. ET.
So what 
On March 1, 2022, the FDA approved Vonjo to treat patients with myelofibrosis, a rare bone marrow disorder. During the clinical trial that led to its approval, 29% of patients treated with Vonjo achieved a significant improvement compared to just 3% of the placebo group. How well those study results would translate into product sales, though, was uncertain. 
Despite launching during the last month of the three-month period, sales of Vonjo reached $2.3 million during the first quarter, and investors expect a great deal more before the year is through. Jakafi, a competing myelofibrosis treatment from Incyte (NASDAQ: INCY), is a blockbuster that generated $2.1 billion in sales last year.
Image source: Getty Images.

Now what
CTI BioPharma is still losing money hand over fist but it’s probably just a matter of time before it has positive cash flow to report. The National Comprehensive Cancer Network recently named Vonjo as a recommended treatment for different groups of myelofibrosis patients who aren’t eligible for bone marrow transplants. 
CTI BioPharma and biotech stocks across the board have been having a hard time getting investors’ attention recently. As a result, it looks like a bargain right now. Even after Friday’s big gain, the biotech company still sports a modest market cap of just $451 million. If Vonjo’s sales get anywhere close to those of competing treatments, investors who buy CTI BioPharma stock at this price could reap some impressive gains.
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Incyte. The Motley Fool has a disclosure policy. –

What happened

Shares of CTI BioPharma (NASDAQ: CTIC) moved sharply higher after the drugmaker reported first-quarter results Friday morning. Investors were pleased with the initial sales figures for Vonjo, its first approved drug, and pushed the stock price 20.8% higher as of 11:22 a.m. ET.

So what 

On March 1, 2022, the FDA approved Vonjo to treat patients with myelofibrosis, a rare bone marrow disorder. During the clinical trial that led to its approval, 29% of patients treated with Vonjo achieved a significant improvement compared to just 3% of the placebo group. How well those study results would translate into product sales, though, was uncertain. 

Despite launching during the last month of the three-month period, sales of Vonjo reached $2.3 million during the first quarter, and investors expect a great deal more before the year is through. Jakafi, a competing myelofibrosis treatment from Incyte (NASDAQ: INCY), is a blockbuster that generated $2.1 billion in sales last year.

Image source: Getty Images.

Now what

CTI BioPharma is still losing money hand over fist but it’s probably just a matter of time before it has positive cash flow to report. The National Comprehensive Cancer Network recently named Vonjo as a recommended treatment for different groups of myelofibrosis patients who aren’t eligible for bone marrow transplants. 

CTI BioPharma and biotech stocks across the board have been having a hard time getting investors’ attention recently. As a result, it looks like a bargain right now. Even after Friday’s big gain, the biotech company still sports a modest market cap of just $451 million. If Vonjo’s sales get anywhere close to those of competing treatments, investors who buy CTI BioPharma stock at this price could reap some impressive gains.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Incyte. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex Securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here To Get Started
FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here For More Info